Abstract
The antibacterial properties of bismuth are greatly enhanced when bismuth is combined with certain lipophilic thiol compounds. Antibacterial activity was enhanced from 25- to 300-fold by the following seven different thiols, in order of decreasing synergy: 1,3-propanedithiol, dimercaprol (BAL), dithiothreitol, 3-mercapto-2-butanol, beta-mercaptoethanol, 1-monothioglycerol, and mercaptoethylamine. The dithiols produced the greatest synergy with bismuth at optimum bismuth-thiol molar ratios of from 3:1 to 1:1. The monothiols were generally not as synergistic and required molar ratios of from 1:1 to 1:4 for optimum antibacterial activity. The most-active mono- or dithiols were also the most soluble in butanol. The intensity of the yellow formed by bismuth-thiol complexes reflected the degree of chelation and correlated with antibacterial potency at high molar ratios. The bismuth-BAL compound (BisBAL) was active against most bacteria, as assessed by broth dilution, agar diffusion, and agar dilution analyses. Staphylococci (MIC, 5 to 7 microM Bi3+) and Helicobacter pylori (MIC, 2.2 microM) were among the most sensitive bacteria. Gram-negative bacteria were sensitive (MIC, < 17 microM). Enterococci were relatively resistant (MIC, 63 microM Bi3+). The MIC range for anaerobes was 15 to 100 microM Bi3+, except for Clostridium difficile (MIC, 7.5 microM). Bactericidal activity averaged 29% above the MIC. Bactericidal activity increased with increasing pH and/or increasing temperature. Bismuth-thiol solubility, stability, and antibacterial activity depended on pH and the bismuth-thiol molar ratio. BisBAL was stable but ineffective against Escherichia coli at pH 4. Activity and instability (reactivity) increased with increasing alkalinity. BisBAL was acid soluble at a molar ratio of greater than 3:2 and alkaline soluble at a molar ratio of less than 2:3. In conclusion, certain lipophilic thiol compounds enhanced bismuth antibacterial activity against a broad spectrum of bacteria. The activity, solubility, and stability of BisBAL were strongly dependent on the pH, temperature, and molar ratio. Chelation of bismuth with certain thiol agents enhanced the solubility and lipophilicity of this cationic heavy metal, thereby significantly enhancing its potency and versatility as an antibacterial agent.
Full Text
The Full Text of this article is available as a PDF (231.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Beil W., Birkholz C., Wagner S., Sewing K. F. Bismuth subcitrate and omeprazole inhibit Helicobacter pyloriF1-ATPase. Pharmacology. 1995 May;50(5):333–337. doi: 10.1159/000139299. [DOI] [PubMed] [Google Scholar]
- Bierer D. W. Bismuth subsalicylate: history, chemistry, and safety. Rev Infect Dis. 1990 Jan-Feb;12 (Suppl 1):S3–S8. doi: 10.1093/clinids/12.supplement_1.s3. [DOI] [PubMed] [Google Scholar]
- Chaleil D., Lefevre F., Allain P., Martin G. J. Enhanced bismuth digestive absorption in rats by some sulfhydryl compounds: nmr study of complexes formed. J Inorg Biochem. 1981 Nov;15(3):213–221. doi: 10.1016/s0162-0134(00)80156-7. [DOI] [PubMed] [Google Scholar]
- Cornick N. A., Silva M., Gorbach S. L. In vitro antibacterial activity of bismuth subsalicylate. Rev Infect Dis. 1990 Jan-Feb;12 (Suppl 1):S9–10. doi: 10.1093/clinids/12.supplement_1.s9. [DOI] [PubMed] [Google Scholar]
- Domenico P., O'Leary R., Cunha B. A. Differential effects of bismuth and salicylate salts on the antibiotic susceptibility of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 1992 Feb;11(2):170–175. doi: 10.1007/BF01967072. [DOI] [PubMed] [Google Scholar]
- DuPont H. L., Ericsson C. D. Prevention and treatment of traveler's diarrhea. N Engl J Med. 1993 Jun 24;328(25):1821–1827. doi: 10.1056/NEJM199306243282507. [DOI] [PubMed] [Google Scholar]
- Figueroa-Quintanilla D., Salazar-Lindo E., Sack R. B., León-Barúa R., Sarabia-Arce S., Campos-Sánchez M., Eyzaguirre-Maccan E. A controlled trial of bismuth subsalicylate in infants with acute watery diarrheal disease. N Engl J Med. 1993 Jun 10;328(23):1653–1658. doi: 10.1056/NEJM199306103282301. [DOI] [PubMed] [Google Scholar]
- Graham D. Y., Lew G. M., Evans D. G., Evans D. J., Jr, Klein P. D. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. Ann Intern Med. 1991 Aug 15;115(4):266–269. doi: 10.7326/0003-4819-115-4-266. [DOI] [PubMed] [Google Scholar]
- Klapötke T. Biological activity of organometallic bismuth compounds. Biol Met. 1988;1(2):69–76. doi: 10.1007/BF01138064. [DOI] [PubMed] [Google Scholar]
- Manhart M. D. In vitro antimicrobial activity of bismuth subsalicylate and other bismuth salts. Rev Infect Dis. 1990 Jan-Feb;12 (Suppl 1):S11–S15. doi: 10.1093/clinids/12.supplement_1.s11. [DOI] [PubMed] [Google Scholar]
- Marshall B. J. Campylobacter pylori: its link to gastritis and peptic ulcer disease. Rev Infect Dis. 1990 Jan-Feb;12 (Suppl 1):S87–S93. doi: 10.1093/clinids/12.supplement_1.s87. [DOI] [PubMed] [Google Scholar]
- Molina J. A., Calandre L., Bermejo F. Myoclonic encephalopathy due to bismuth salts: treatment with dimercaprol and analysis of CSF transmitters. Acta Neurol Scand. 1989 Mar;79(3):200–203. doi: 10.1111/j.1600-0404.1989.tb03739.x. [DOI] [PubMed] [Google Scholar]
- Newton G. L., Fahey R. C. Determination of biothiols by bromobimane labeling and high-performance liquid chromatography. Methods Enzymol. 1995;251:148–166. doi: 10.1016/0076-6879(95)51118-0. [DOI] [PubMed] [Google Scholar]
- Slikkerveer A., de Wolff F. A. Pharmacokinetics and toxicity of bismuth compounds. Med Toxicol Adverse Drug Exp. 1989 Sep-Oct;4(5):303–323. doi: 10.1007/BF03259915. [DOI] [PubMed] [Google Scholar]
- Wilson A. P. The dangers of BIPP. Lancet. 1994 Nov 12;344(8933):1313–1314. doi: 10.1016/s0140-6736(94)90689-0. [DOI] [PubMed] [Google Scholar]